# Phase 1 Study of OSI-930 in Cancer Patients

> **NCT00513851** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** OSI-930
- **DRUG:** OSI-930

## Key facts

- **NCT ID:** NCT00513851
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2009-07
- **Final completion:** 2009-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2011-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00513851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00513851, "Phase 1 Study of OSI-930 in Cancer Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00513851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*